Experience

Davis Polk advised the joint book-running managers, in connection with an SEC-registered offering by Zoetis Inc. of $750 million aggregate principal amount of its 2.000% senior notes due…

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…

Davis Polk advised the representatives of the several underwriters on an SEC-registered offering by Anthem, Inc. of $2.5 billion in aggregate principal amount of senior notes, consisting of…

Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.0 billion aggregate principal amount of its 2.250% notes due 2050…

Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by NeoGenomics, Inc. of 4,400,000 shares of its common stock and $175 million…

Davis Polk advised the dealer manager in connection with the private offer by Envision Healthcare Corporation to exchange approximately $106 million of its new first-lien senior secured…

Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered common stock and pre-funded warrants offering by Aeglea, including the full exercise…

Davis Polk advised the representatives of the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.250% senior notes due 2030…

Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on Rule 144A and Regulation S…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coherus BioSciences, Inc. of $200 million aggregate principal amount of its…